Aggregator

“Nonaward” notices discontinue grants from the Agency for Healthcare Research and Quality whose annual funds had been stalled

Youlin Chen analyzed earthquake data that can also aid nuclear-test monitoring

A drug originally developed for spinal cord injury may offer a fresh approach to treating Alzheimer’s disease. In mouse studies, KCL-286 repaired dangerous DNA damage, reduced inflammation, and targeted multiple disease-related pathways instead of focusing on just amyloid or tau. Since it has already cleared an initial human safety trial, researchers believe it could move more quickly into Alzheimer’s clinical testing.

Some countries face reductions of more than 90%, new report reveals, raising fears of devastating impacts on global health and education

A new experimental treatment may have found a way to outsmart glioblastoma’s toughest defense: the blood-brain barrier. Researchers used sugar-coated nanoparticles to ferry genetic instructions that restore a key tumor-suppressing protein directly into brain cancer cells. In mouse studies, the therapy increased median survival by 50% while shrinking tumors without noticeable damage to other organs.

Staffers complain that Salk allowed circadian rhythms researcher Satchidananda Panda to depart quietly, while the allegations and findings remain under wraps

An international study found that finerenone slows kidney function decline and reduces the risk of serious kidney and cardiovascular complications in people with chronic kidney disease who do not have diabetes. The results could open the door to a much-needed new treatment option for the majority of CKD patients who have long had limited choices.

Ancient Teghaza meteorite hints at granitelike crust and shows Mars was already losing its water 4.1 billion years ago

Finding points to potential way to break apart dangerous biofilms without antibiotics

National Academies report says the fast-growing field can boost confidence with more rigorous results

The extent to which the cerebrovasculature is affected in various brain disorders is still not well understood. To address this, we established a transcriptomic repository of major vascular cell types and microglia to compare the global transcriptomic response in mouse models of three human brain disorders linked to neuroinflammation and associated vascular reactivity: Alzheimer's disease (AD), traumatic brain injury (TBI), and cerebral autosomal dominant arteriopathy with subcortical infarcts...

Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder marked by progressive cognitive decline, yet its transcriptional regulatory architecture remains poorly understood. Here, we model sample-specific gene regulatory networks (GRNs) from dorsolateral prefrontal cortex transcriptomes of 87 individuals with AD and 67 non-cognitively impaired (NCI) controls and use a machine learning classifier to detect consistent disease-specific network features. This sample-specific network...

Proteostasis collapse, a hallmark of aging and neurodegeneration like Alzheimer's disease (AD), causes irreversible damage in late life. Whether late-life proteostasis capacity is developmentally programmed remains unclear, as mechanistic studies requiring lifelong tracking and molecular manipulation are challenging or impossible in long-lived species. Using C. elegans as a lifelong, genetically tractable AD model, we uncover a critical early-life window during which reducing TIP60/NuA4...

Bone marrow aging compromises hematopoiesis and immunity, yet whether these processes are modifiable in primates remains unexplored. Here, we map the single-cell transcriptomic landscape of primate bone marrow aging and demonstrate that long-term oral vitamin C (VC) supplementation attenuates selected molecular and progenitor-level decline. Aging drives severe common lymphoid progenitor (CLP) depletion, myeloid-biased hematopoietic stem and progenitor cell (HSPC) output, and anatomical...